UPDATED: Stephen Hahn makes first post-FDA move, joining board of under-the-radar Philadelphia company
Pharma critics argue there is a revolving door between the FDA and industry, as career staffers rotate between the regulatory body and the companies they regulate. On Tuesday, former agency chief Stephen Hahn added another arrow to their quivers.
Hahn has accepted a board position at Blackfynn, a little-known company in Philadelphia with several former researchers from the University of Pennsylvania. It’s Hahn’s first move into the industry since resigning as FDA commissioner on Jan. 20 at the conclusion of President Trump’s administration.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 102,900+ biopharma pros reading Endpoints daily — and it's free.